Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Carcinoma, Neuroendocrine 1

Interventions

Cyclophosphamide 27Busulfan 25fludarabine phosphate 24Antilymphocyte Serum 20Tacrolimus 18Peripheral Blood Stem Cell Transplantation 18Cyclosporine 15Radiotherapy 14Mycophenolic Acid 14Methotrexate 14Melphalan 12Filgrastim 11Whole-Body Irradiation 10Methylprednisolone 10Cord Blood Stem Cell Transplantation 9Etoposide 7Cytarabine 5sargramostim 4Thiotepa 4Thalidomide 4Specimen Handling 4Sirolimus 4Rituximab 4Cyclosporins 4Biopsy 4Alemtuzumab 4ruxolitinib 3Flow Cytometry 3Arsenic Trioxide 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myelodysplastic-Myeloproliferative Diseases × iadademstat × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡